Biogen's Alzheimer's drug slows cognitive decline in midstage study, eyeing Phase 3
TL;DR Summary
In a mid-stage Phase 2 trial, Biogen's experimental Alzheimer’s drug diranersen slowed cognitive decline to rates similar to approved therapies and reduced brain tau, a result that supports advancing to Phase 3 pending confirmation.
- Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows STAT
- An experimental Alzheimer's drug shows some promise as researchers hunt new approaches AP News
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease Biogen
- All eyes on data on Biogen’s tau therapy STAT
- Biogen Shares Fall as Alzheimer’s Tau Trial Data Disappoint Bloomberg.com
Reading Insights
Total Reads
1
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
93%
464 → 34 words
Want the full story? Read the original article
Read on STAT